Purple Biotech Ltd.
PPBT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $196 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Cost of Goods Sold | $186 | $196 | $0 | $0 |
| Gross Profit | -$186 | -$0 | -$0 | -$0 |
| % Margin | – | -0.1% | – | – |
| R&D Expenses | $7,620 | $17,034 | $16,320 | $11,827 |
| G&A Expenses | $2,935 | $4,844 | $5,962 | $5,821 |
| SG&A Expenses | $2,935 | $4,844 | $5,962 | $5,821 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $450 | $393 | $321 | $12 |
| Operating Expenses | $11,005 | -$22,467 | $22,603 | $17,934 |
| Operating Income | -$11,005 | -$22,271 | -$22,603 | -$17,934 |
| % Margin | – | -11,374.1% | – | – |
| Other Income/Exp. Net | $3,726 | $2,294 | $843 | $108 |
| Pre-Tax Income | -$7,279 | -$19,977 | -$21,760 | -$17,826 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7,240 | -$20 | -$21,668 | -$18,384 |
| % Margin | – | -10.2% | – | – |
| EPS | -4.42 | -0.16 | -0.23 | -0.21 |
| % Growth | -2,662.5% | 30.4% | -9.5% | – |
| EPS Diluted | -4.42 | -0.16 | -0.23 | -0.21 |
| Weighted Avg Shares Out | 2,586 | 1,231 | 924 | 890 |
| Weighted Avg Shares Out Dil | 2,586 | 1,231 | 924 | 890 |
| Supplemental Information | – | – | – | – |
| Interest Income | $260 | $474 | $532 | $320 |
| Interest Expense | $447 | $2,182 | $67 | $212 |
| Depreciation & Amortization | $186 | $46 | $201 | $231 |
| EBITDA | -$7,052 | -$19,875 | -$21,492 | -$17,516 |
| % Margin | – | -10,150.5% | – | – |